Shares of ANCHIANO THERAP/S (NASDAQ:ANCN) have received a consensus broker rating score of 1.00 (Strong Buy) from the three brokers that provide coverage for the company, Zacks Investment Research reports. Three investment analysts have rated the stock with a strong buy rating.
Brokers have set a one year consensus price objective of $16.00 for the company and are anticipating that the company will post ($0.78) earnings per share for the current quarter, according to Zacks. Zacks has also assigned ANCHIANO THERAP/S an industry rank of 51 out of 256 based on the ratings given to related companies.
A number of research analysts have recently commented on ANCN shares. Robert W. Baird started coverage on shares of ANCHIANO THERAP/S in a research report on Tuesday, May 28th. They set an “outperform” rating and a $12.00 target price on the stock. Zacks Investment Research raised shares of HENKEL AG & CO/S from a “sell” rating to a “hold” rating in a report on Thursday, June 6th.
ANCHIANO THERAP/S (NASDAQ:ANCN) last released its earnings results on Wednesday, May 22nd. The company reported ($3.50) earnings per share (EPS) for the quarter. Research analysts predict that ANCHIANO THERAP/S will post -3.78 earnings per share for the current fiscal year.
Several institutional investors have recently added to or reduced their stakes in ANCN. Meitav Dash Investments Ltd. purchased a new position in shares of ANCHIANO THERAP/S in the 1st quarter valued at $177,000. Delek Group Ltd. acquired a new position in ANCHIANO THERAP/S during the first quarter worth about $176,000. Kennedy Capital Management Inc. acquired a new position in ANCHIANO THERAP/S during the first quarter worth about $1,359,000. Finally, FMR LLC acquired a new position in ANCHIANO THERAP/S during the first quarter worth about $288,000. Institutional investors and hedge funds own 6.18% of the company’s stock.
ANCHIANO THERAP/S Company Profile
Anchiano Therapeutics Ltd, a clinical-stage biotechnology company, develops gene therapies to treat early-stage bladder cancer. It is primarily developing Inodiftagene that is in various clinical trials for the treatment of non-muscle-invasive bladder cancer. The company was formerly known as BioCancell Ltd.
Read More: Float
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ANCHIANO THERAP/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANCHIANO THERAP/S and related companies with MarketBeat.com's FREE daily email newsletter.